Unresectable Hepatocellular Carcinoma (HCC) Clinical Trial
Official title:
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
The primary purpose of this study is to assess the single- and multiple-dose pharmacokinetic (PK) profile of lenvatinib in Chinese participants with unresectable Hepatocellular Carcinoma (HCC).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05630937 -
Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05967143 -
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
|